Order Article Reprints

Izumi K, Matsumoto R, Ito Y, Hoshi S, Matsubara N, Yamasaki T, Mizowaki T, Komaru A, Nomura S, Hattori T, et al. [¹⁷⁷Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan. Cancers. 2025; 17(14):2351. https://doi.org/10.3390/cancers17142351

Izumi, Kouji, Ryuji Matsumoto, Yusuke Ito, Seiji Hoshi, Nobuaki Matsubara, Toshinari Yamasaki, Takashi Mizowaki, Atsushi Komaru, Satoshi Nomura, Toru Hattori, and et al. 2025. "[¹⁷⁷Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan" Cancers 17, no. 14: 2351. https://doi.org/10.3390/cancers17142351

Izumi, K., Matsumoto, R., Ito, Y., Hoshi, S., Matsubara, N., Yamasaki, T., Mizowaki, T., Komaru, A., Nomura, S., Hattori, T., Kambara, H., Alanee, S., Hosono, M., & Kinuya, S. (2025). [¹⁷⁷Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in Japan. Cancers, 17(14), 2351. https://doi.org/10.3390/cancers17142351